RWC Asset Management LLP Lowers Stock Holdings in iRhythm Technologies $IRTC

Posted by Francis Steltz on Jun 8th, 2026

RWC Asset Management LLP lowered its holdings in iRhythm Technologies (NASDAQ:IRTC – Free Report) by 99.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,454 shares of the company’s stock after selling 1,694,141 shares during the period. RWC Asset Management LLP’s holdings in iRhythm Technologies were worth $258,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in IRTC. Tudor Investment Corp ET AL purchased a new stake in shares of iRhythm Technologies in the third quarter valued at $3,439,800,000. Arrowstreet Capital Limited Partnership grew its position in shares of iRhythm Technologies by 6,415.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 541,039 shares of the company’s stock valued at $93,053,000 after purchasing an additional 532,735 shares during the period. Polar Capital Holdings Plc grew its position in shares of iRhythm Technologies by 24,782.1% in the third quarter. Polar Capital Holdings Plc now owns 335,908 shares of the company’s stock valued at $57,773,000 after purchasing an additional 334,558 shares during the period. Holocene Advisors LP boosted its holdings in iRhythm Technologies by 2,023.1% in the second quarter. Holocene Advisors LP now owns 313,094 shares of the company’s stock valued at $48,204,000 after acquiring an additional 298,347 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in iRhythm Technologies by 189.2% in the fourth quarter. Assenagon Asset Management S.A. now owns 225,205 shares of the company’s stock valued at $39,960,000 after acquiring an additional 147,329 shares during the last quarter.

iRhythm Technologies Stock Performance

NASDAQ:IRTC opened at $108.11 on Monday. The company has a debt-to-equity ratio of 4.03, a quick ratio of 4.98 and a current ratio of 5.17. iRhythm Technologies has a one year low of $101.75 and a one year high of $212.00. The business’s 50-day simple moving average is $117.67 and its 200 day simple moving average is $143.32. The stock has a market cap of $3.55 billion, a price-to-earnings ratio of -125.71 and a beta of 1.27.

iRhythm Technologies (NASDAQ:IRTC – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.21. iRhythm Technologies had a negative return on equity of 10.26% and a negative net margin of 3.53%.The business had revenue of $199.39 million for the quarter, compared to analysts’ expectations of $194.11 million. During the same quarter in the previous year, the firm posted ($0.97) earnings per share. The company’s revenue was up 25.6% compared to the same quarter last year. As a group, sell-side analysts predict that iRhythm Technologies will post 0.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. JPMorgan Chase & Co. reduced their target price on iRhythm Technologies from $215.00 to $175.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Citigroup lifted their target price on iRhythm Technologies from $155.00 to $157.00 and gave the company a “buy” rating in a report on Monday, May 4th. Canaccord Genuity Group reduced their target price on iRhythm Technologies from $180.00 to $152.00 and set a “buy” rating on the stock in a report on Monday, June 1st. HC Wainwright reiterated a “buy” rating on shares of iRhythm Technologies in a report on Monday, June 1st. Finally, The Goldman Sachs Group reduced their target price on iRhythm Technologies from $184.00 to $147.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $189.69.

Get Our Latest Stock Report on IRTC

Insiders Place Their Bets

In other news, Director Abhijit Y. Talwalkar acquired 5,312 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $10.71 per share, with a total value of $56,891.52. Following the completion of the acquisition, the director directly owned 25,611 shares in the company, valued at $274,293.81. This represents a 26.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.98% of the stock is currently owned by corporate insiders.

iRhythm Technologies Company Profile

(Free Report)

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.